GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vivoryon Therapeutics NV (FRA:05Y) » Definitions » Graham Number

Vivoryon Therapeutics NV (FRA:05Y) Graham Number : €N/A (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Vivoryon Therapeutics NV Graham Number?

Graham Number is a figure that measures a stock's fundamental value by taking into account the company's earnings per share and book value per share. The Graham number is the upper bound of the price range that a defensive investor should pay for the stock. According to the theory, any stock price below the Graham number is considered undervalued, and thus worth investing in.

As of today (2024-06-07), the stock price of Vivoryon Therapeutics NV is €2.62. Vivoryon Therapeutics NV's graham number for the quarter that ended in Dec. 2023 was €N/A. Therefore, Vivoryon Therapeutics NV's Price to Graham Number ratio for today is N/A.

The historical rank and industry rank for Vivoryon Therapeutics NV's Graham Number or its related term are showing as below:

FRA:05Y's Price-to-Graham-Number is not ranked *
in the Biotechnology industry.
Industry Median: 1.99
* Ranked among companies with meaningful Price-to-Graham-Number only.

Graham Number is a combination of asset valuation and earnings power valuation. It is a very conservative way of valuing a stock.


Vivoryon Therapeutics NV Graham Number Historical Data

The historical data trend for Vivoryon Therapeutics NV's Graham Number can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vivoryon Therapeutics NV Graham Number Chart

Vivoryon Therapeutics NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Graham Number
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Vivoryon Therapeutics NV Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Graham Number Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Vivoryon Therapeutics NV's Graham Number

For the Biotechnology subindustry, Vivoryon Therapeutics NV's Price-to-Graham-Number, along with its competitors' market caps and Price-to-Graham-Number data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vivoryon Therapeutics NV's Price-to-Graham-Number Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vivoryon Therapeutics NV's Price-to-Graham-Number distribution charts can be found below:

* The bar in red indicates where Vivoryon Therapeutics NV's Price-to-Graham-Number falls into.



Vivoryon Therapeutics NV Graham Number Calculation

Graham Number is a concept based on Ben Graham's conservative valuation of companies.

Vivoryon Therapeutics NV's Graham Number for the fiscal year that ended in Dec. 2023 is calculated as

Graham Number
=sqrt of (22.5* Tangible Book per Share *EPS without NRI)
=sqrt of (22.5*0.972*-1.12)
=N/A

Vivoryon Therapeutics NV's Graham Number for the quarter that ended in Dec. 2023 is calculated as

Graham Number
=sqrt of (22.5*Tangible Book per Share*EPS without NRI (TTM))
=sqrt of (22.5*0.972*-1.12)
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vivoryon Therapeutics NV  (FRA:05Y) Graham Number Explanation

Ben Graham actually did not publish a formula like this. But he wrote in The Intelligent Investor (1948 version) regarding to the criteria for purchases:

Current price should not be more than 15 times average earnings of the past three years.

Current price should not be more than 1.5 times the book value last reported. However, a multiplier of earnings below 15 could justify a correspondingly higher multiplier of assets. As a rule of thumb we suggest that the product of the multiplier times the ratio of price to book value should not exceed 22.5. (This figure corresponds to 15 times earnings and 1.5 times book value. It would admit an issue selling at only 9 times earnings and 2.5 times asset value, etc.)

Unlike valuation methods such as DCF or Discounted Earnings, the Graham number does not take growth into the valuation. Unlike the valuation methods based on book value alone, it takes into account the earnings power. Therefore, the Graham Number is a combination of asset valuation and earnings power valuation.

In general, the Graham number is a very conservative way of valuing a stock. It cannot be applied to companies with negative book values.

Vivoryon Therapeutics NV's Price to Graham number Ratio for today is calculated as

Price to Graham number=Share Price (Today)/Graham number (Q: Dec. 2023 )
=2.62/N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Please keep these in mind:

1. Graham Number does not take growth into account. Therefore it underestimates the values of the companies that have good earnings growth. We feel that if the earnings per share grows more than 10% a year, Graham Number underestimates the value.
2. Graham Number punishes the companies that have temporarily low earnings. Therefore, an average of earnings makes more sense in the calculation of Graham Number.
3. Graham Numbers underestimates companies that are light with book.


Vivoryon Therapeutics NV Graham Number Related Terms

Thank you for viewing the detailed overview of Vivoryon Therapeutics NV's Graham Number provided by GuruFocus.com. Please click on the following links to see related term pages.


Vivoryon Therapeutics NV (FRA:05Y) Business Description

Traded in Other Exchanges
Address
Weinbergweg 22, Halle, SN, DEU, 06120
Vivoryon Therapeutics NV is a Germany-based biopharmaceutical company engaged in the activities of research and development, preclinical and clinical trials. It is focused on the development of therapeutic products for the treatment of Alzheimer's disease and cancer. The company's pipeline products include PQ912 and PQ1565. Geographically, the majority is from Greater China.

Vivoryon Therapeutics NV (FRA:05Y) Headlines

No Headlines